UBS Group
VNDA icon

UBS Group’s Vanda Pharmaceuticals VNDA Stock Holding History

UBS Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-400
Closed -$3.53K – 11216
2025
Q4 		$3.53K Buy
+400
New +$2.2K ﹤0.01% 9002
2024
Q4 		– Sell
-63,800
Closed -$299K – 10442
2024
Q3 		$299K Buy
+63,800
New +$342K ﹤0.01% 5570
2017
Q4 		– Sell
-25,000
Closed -$448K – 8121
2017
Q3 		$448K Buy
+25,000
New +$418K ﹤0.01% 4296
2015
Q2 		– Sell
-145,800
Closed -$1.36M – 8869
2015
Q1 		$1.36M Buy
145,800
+145,500
+48,500% +$1.64M ﹤0.01% 3296
2014
Q4 		$4K Buy
+300
New +$3.55K ﹤0.01% 9134

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's VNDA Position: Q2 2026 in Review

UBS Group increased its Vanda Pharmaceuticals (VNDA) stake by 18% in Q2 2026, buying an estimated $301K and bringing the position to 303,191 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #5172.

UBS Group first reported a position in VNDA in Q4 2014 and has held it in 47 quarters since. The position peaked at $4.45M in Q4 2018. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • UBS Group held 303,191 shares of Vanda Pharmaceuticals worth $1.86M as of Q2 2026.
  • UBS Group bought 46,021 Vanda Pharmaceuticals shares in Q2 2026, an estimated $301K.
  • Vanda Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5172 holding.
  • UBS Group first reported a position in Vanda Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Vanda Pharmaceuticals position peaked at $4.45M in Q4 2018.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.